Journals on Biomedical Engineering - BJSTR Journal

Abstract

The estimation of #prostate-specific antigen (PSA) levels in the blood is the most important biomarker in the diagnosis, monitoring and management of prostate cancer [1]. In the community, total PSA testing is used to monitor patients with prostate cancer and to screen men at risk of prostate cancer. Usual practice is for a blood sample to be collected at a community location, such as a GP surgery, and transported to a laboratory, or for the patient to travel to a local hospital to give the sample. The PSA result is usually communicated to the patient 48 hours later, and a further appointment is often required to discuss the results. Point-of- care (POCT) PSA testing would eliminate this delay and call-back, thus enabling a real-time discussion to take place about the PSA result and reducing the number of clinic visits required. Once the patient has made an informed decision to have the test, he could leave the setting with his PSA result and the GP would be alerted to an abnormal value the same day. This would facilitate timely discussion, further investigations, or onward referral, if necessary, to urology [2].

For more articles on BJSTR Journal please click on https://biomedres.us/

For more Biomedical Engineering Articles on BJSTR

https://biomedres.us/fulltexts/BJSTR.MS.ID.001822.php

An Evaluation of the Novel i-CHROMA™ Point-of-Care Testing (POCT) Method for the Analysis of Prostate-Specific Antigen (PSA) in Serum by John Bolodeoku in BJSTR